Comparative Pharmacology
Head-to-head clinical analysis: KENACORT versus RAYOS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KENACORT versus RAYOS.
KENACORT vs RAYOS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Glucocorticoid receptor agonist; inhibits phospholipase A2, reduces prostaglandin and leukotriene synthesis; suppresses cytokine production and immune cell migration.
Synthetic glucocorticoid with anti-inflammatory, immunosuppressive, and metabolic effects; binds to glucocorticoid receptor, modulating gene expression and inhibiting phospholipase A2, cytokine production, and immune cell activity.
Kenacort (triamcinolone acetonide) is a corticosteroid. For adults, typical dosing is 40-80 mg intramuscularly (deep intragluteal) as a single injection; oral tablets: 4-48 mg/day divided every 6-12 hours; intra-articular: 5-40 mg depending on joint size.
Initial adult dose 5-60 mg orally once daily, adjusted based on disease severity and response. Typically administered as a single dose in the morning with food.
None Documented
None Documented
Terminal elimination half-life: 2-5 hours (triamcinolone acetonide). Clinical context: Short half-life supports alternate-day dosing for chronic conditions; however, adrenal suppression may persist longer.
2-3 hours (terminal); prolonged in hepatic impairment; circadian-timed formulation intended for once-daily morning dosing.
Renal: 25-30% as unchanged drug and metabolites. Biliary/fecal: 50-70% as metabolites, with enterohepatic circulation.
Renal: ~80% as inactive metabolites; fecal: ~5%; biliary: small amount.
Category C
Category C
Corticosteroid
Corticosteroid